Medicine and Dentistry
Psoriasis
100%
Biological Product
53%
Biological Therapy
50%
Systemic Therapy
44%
Cohort Analysis
37%
Adalimumab
24%
Ustekinumab
23%
Etanercept
23%
Cohort Study
18%
Adverse Event
16%
Psoriasis Area and Severity Index
15%
Dermatology Life Quality Index
10%
Diseases
10%
Methotrexate
9%
Prevalence
9%
Medical Aspects of Alcohol Misuse
9%
Alcohol Consumption
9%
Folliculitis
9%
Cyclosporine
8%
Treatment Response
6%
Pharmacovigilance
6%
Mineral Fiber
6%
Psoriatic Arthritis
5%
Disease Duration
5%
Fumaric Acid
5%
Infliximab
5%
Etretin
5%
Pharmacology, Toxicology and Pharmaceutical Science
Psoriasis
90%
Biological Product
66%
Cohort Study
50%
Ustekinumab
42%
Adalimumab
41%
Etanercept
40%
Respiratory Tract Disease
21%
Contact Dermatitis
18%
Psoriatic Arthritis
15%
Adverse Event
15%
Methotrexate
10%
Disease
10%
Lung Cancer
10%
Prevalence
9%
Voluntary Reporting
9%
Occupational Eczema
9%
Comorbidity
8%
Ciclosporin
7%
Mineral Fiber
7%
Disease Duration
6%
Pharmacovigilance
6%
Asthma
5%
Larynx Cancer
5%
Immunology and Microbiology
Biological Product
54%
Adalimumab
22%
Etanercept
21%
Ustekinumab
21%
Psoriatic Arthritis
16%
Comorbidity
9%
Prevalence
9%
Ciclosporin
7%
Allergic Pneumonitis
6%
